Zanubrutinib for R/R primary CNS lymphoma: the initial results of the PRiZM+ platform study [Video]

Chris Fox, MBChB(Hons), MRCP, FRCPath, University of Nottingham, Nottingham, UK, outlines the initial results from the PRiZM+ Phase II platform study (ISRCTN90634455) of zanubrutinib in patients with relapsed/refractory (R/R) primary central nervous system (CNS) lymphoma. Dr Fox presents the findings of the zanubrutinib monotherapy cohort and highlights that, despite this being a difficult-to-treat patient population with a short duration of first response, the overall response rate (ORR) was encouraging. The PRiZM+ study will now look at zanubrutinib in combination with other agents. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.